Usefulness of Red Cell Distribution Width as a Prognostic Marker in Pulmonary Hypertension††Conflicts of interest: Dr. Gomberg-Maitland has received research grant support from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; CoTherix, Inc., South San Francisco, California; Encysive Pharmaceuticals Inc., Houston, Texas; Gilead Sciences Inc., Foster City, California; Eli Lilly/ICOS, Indianapolis, Indiana; Pfizer Inc., New York, New York; and United Therapeutics, Silver Spring, Maryland. Dr. Gomberg-Maitland has served as a consultant and/or on advisory boards for Encysive Pharmaceuticals Inc., Gilead Sciences Inc., Pfizer Inc., and United Therapeutics. Dr. Shah has received research grant support from Actelion Pharmaceuticals Ltd. (Entelligence Young Investigator Award) and is also the recipient of a Scientist Development Grant from the American Heart Association, Dallas, Texas.

詳細情報 詳細情報について

• CRID

  1361418520820517504

• DOI

  10.1016/j.amjcard.2009.05.016

• ISSN

  00029149

• Web Site

  https://api.elsevier.com/content/article/PII:S0002914909010510?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S0002914909010510?httpAccept=text/plain

• データソース種別

  • Crossref